Indication: Miscellaneous Malignancies
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Sub-indication: Miscellaneous Malignancies
Drug Study
Principal Investigator: John Hamm, M.D.Norton Cancer Institute
Sponsor: Seattle Genetics, Inc
Learn more at ClinicalTrials.gov
Email for more information: CancerResearch@nortonhealthcare.org
